Article
Therapeutic Impact of Third-generation Tyrosine Kinase Inhibitors on Lung Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Mutations: A Case Description and Systematic Literature Review.
Internal medicine (Tokyo, Japan) - 1 Sept 2026
Minematsu Naoto, Imai Yoko, Hirano Toshiyuki, Kakimoto Tomoo
Abstract excerpt
Epidermal growth factor receptor (EGFR) mutations are uncommon in lung squamous cell carcinoma (SQC). However, the role of third-generation EGFR-tyrosine kinase inhibitors (TKIs) remains unclear. The present study provides a case description and a systematic literature review of 34 eligible cases. Third-generation EGFR-TKIs demonstrate superior initial responsiveness compared to earlier-generation TKIs. The...
Read the complete abstract on PubMedTopics
- Humans
- Aniline Compounds
- Carcinoma, Squamous Cell
- ErbB Receptors
- Indoles
- Lung Neoplasms